Sanofi-Aventis China R&D Head Jiang On Fast And Furious Adaptation In China
Sanofi-Aventis is grabbing a larger share of the emerging markets from many of its rivals, such as Pfizer and Wyeth, Novartis, GlaxoSmithKline and Merck and Schering-Plough. Part of the reason behind Sanofi's success is its aggressive strategy in China, where it currently has 3,500 employees in vaccines, R&D, commercial operations and manufacturing. Sanofi-Aventis China R&D Head Frank Jiang sat down for a recent interview to discuss the environment in China and how Sanofi is approaching R&D there.
You may also be interested in...
Sanofi Aventis has already cut 14 projects from its pipeline since February, but there could be more coming by the end of the year - and with a possible Plavix successor among the compounds in limbo, those decisions will be a true test of whether Sanofi is really going to steer clear of "me-too" type products that may be a tougher commercial climb
Sanofi-Aventis Sees Diversifying In China As Key To Success; Expands Capacity For Diabetes Treatment Lantus
SHANGHAI - Sanofi-Aventis announced a series of expansion plans in China aimed at diversifying its portfolio, the CEO said April 21 during his first trip to China
SHANGHAI - Sanofi-Aventis recently expanded its R&D presence in China to meet the rapid growth of clinical programs and broaden its activities from drug-target identification to late-stage clinical studies